Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study

Cancer

Volumn 119, Issue 20, 2013, Pages 3596-3603

  McCarthy, Anne Marie ^a   Bristol, Mirar ^a   Fredricks, Tracey ^a   Wilkins, Lache ^a   Roelfsema, Irene ^a   Liao, Kaijun ^a   Shea, Judy A ^a   Groeneveld, Peter ^a,b   Domchek, Susan M ^a   Armstrong, Katrina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

BRCA1 2; breast cancer; cancer registry; genetic testing; physician recommendations

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER THERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; OVARY CANCER; PHYSICIAN; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE; UNITED STATES;

BRCA1/2; BREAST CANCER; CANCER REGISTRY; GENETIC TESTING; PHYSICIAN RECOMMENDATIONS;

ADOLESCENT; ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PENNSYLVANIA; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84885175017     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28268     Document Type: Article

References (26)

1. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22: 1055-1062. (Pubitemid 41095038)
2. Rebbeck TR, Kauff ND, Domchek SM,. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009; 101: 80-87.
3. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304: 967-975.
4. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20: 1480-1490. (Pubitemid 34260526)
5. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008; 98: 1457-1466. (Pubitemid 351543573)
6. Daly MB, Axilbund JE, Buys S, et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1. 2012. www.nccn.org/ professionals/physician-gls/pdf/genetics-screening.pdf. Accessed September 7, 2012
7. Julian-Reynier C, Sobol H, Sevilla C, Nogues C, Bourret P,; French Cancer Genetic Network. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. The French Cancer Genetic Network. Psychooncology. 2000; 9: 504-510. (Pubitemid 32010923)
8. Cappelli M, Surh L, Humphreys L, et al. Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. Clin Genet. 1999; 55: 419-430. (Pubitemid 29335638)
9. Kieran S, Loescher LJ, Lim KH,. The role of financial factors in acceptance of clinical BRCA genetic testing. Genet Test. 2007; 11: 101-110. (Pubitemid 46557364)
10. Finlay E, Stopfer JE, Burlingame E, et al. Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Genet Test. 2008; 12: 81-91. (Pubitemid 351457781)
11. Ropka ME, Wenzel J, Phillips EK, Siadaty M, Philbrick JT,. Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev. 2006; 15: 840-855. (Pubitemid 43823507)
12. Olaya W, Esquivel P, Wong JH, et al. Disparities in BRCA testing: when insurance coverage is not a barrier. Am J Surg. 2009; 198: 562-565.
13. Samphao S, Wheeler AJ, Rafferty E, et al. Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. Am J Surg. 2009; 198: 538-543.
14. Peters N, Domchek SM, Rose A, Polis R, Stopfer J, Armstrong K,. Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test. 2005; 9: 48-53. (Pubitemid 40586430)
15. Brown KL, Hutchison R, Zinberg RE, McGovern MM,. Referral and experience with genetic testing among women with early onset breast cancer. Genet Test. 2005; 9: 301-305. (Pubitemid 43099622)
16. Armstrong K, Stopfer J, Calzone K, Fitzgerald G, Coyne J, Weber B,. What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations. Genet Test. 2002; 6: 115-118.
17. Schwartz MD, Lerman C, Brogan B, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1003-1007. (Pubitemid 40478572)
18. Katz SJ, Lantz PM, Janz NK, et al. Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol. 2005; 23: 5526-5533.
19. Kwon JS, Daniels MS, Sun CC, Lu KH,. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol. 2010; 28: 675-682.
20. Wang G, Beattie MS, Ponce NA, Phillips KA,. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med. 2011; 13: 1045-1050.
21. Lowstuter KJ, Sand S, Blazer KR, et al. Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med. 2008; 10: 691-698.
22. Genetic Information Nondiscrimination Act of 2008. Pub L No. 110-233, 122 Stat 881.
23. Ruddy KJ, Gelber S, Shin J, et al. Genetic testing in young women with breast cancer: results from a Web-based survey. Ann Oncol. 2010; 21: 741-747.
24. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010; 8: 562-594.
25. Koil CE, Everett JN, Hoechstetter L, Ricer RE, Huelsman KM,. Differences in physician referral practices and attitudes regarding hereditary breast cancer by clinical practice location. Genet Med. 2003; 5: 364-369. (Pubitemid 37264985)
26. Bober SL, Hoke LA, Duda RB, Tung NM,. Recommendation recall and satisfaction after attending breast/ovarian cancer risk counseling. J Genet Counsel. 2007; 16: 755-762. (Pubitemid 350077235)